CL2017001687A1 - Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina. - Google Patents

Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina.

Info

Publication number
CL2017001687A1
CL2017001687A1 CL2017001687A CL2017001687A CL2017001687A1 CL 2017001687 A1 CL2017001687 A1 CL 2017001687A1 CL 2017001687 A CL2017001687 A CL 2017001687A CL 2017001687 A CL2017001687 A CL 2017001687A CL 2017001687 A1 CL2017001687 A1 CL 2017001687A1
Authority
CL
Chile
Prior art keywords
illnesses
inhibitors
pirrolo
pyrazolopyrimidines
ubiquitin
Prior art date
Application number
CL2017001687A
Other languages
English (en)
Spanish (es)
Inventor
Ann-Marie Campbell
R Bruce Diebold
Anna Ericsson
Stepahnos Ioannidis
Adam Charles Talbot
Bruce Follows
Alexandre Joseph Buckmelter
Minghua Wang
Darby Rye Schmidt
David Joseph Guerin
Justin A Caravella
Jr David R Lancia
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of CL2017001687A1 publication Critical patent/CL2017001687A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2017001687A 2014-12-30 2017-06-23 Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina. CL2017001687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098141P 2014-12-30 2014-12-30

Publications (1)

Publication Number Publication Date
CL2017001687A1 true CL2017001687A1 (es) 2018-03-23

Family

ID=55310894

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001687A CL2017001687A1 (es) 2014-12-30 2017-06-23 Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina.

Country Status (22)

Country Link
US (4) US9902728B2 (enExample)
EP (2) EP3623372A1 (enExample)
JP (1) JP6649388B2 (enExample)
KR (1) KR102581827B1 (enExample)
CN (1) CN107406451B (enExample)
AR (1) AR103297A1 (enExample)
AU (2) AU2015374170B2 (enExample)
CA (1) CA2972797C (enExample)
CL (1) CL2017001687A1 (enExample)
CO (1) CO2017006997A2 (enExample)
EA (1) EA038204B1 (enExample)
EC (1) ECSP17049010A (enExample)
ES (1) ES2768996T3 (enExample)
IL (1) IL252773A0 (enExample)
MA (1) MA40706A1 (enExample)
MX (2) MX373788B (enExample)
PH (1) PH12017501224A1 (enExample)
SA (1) SA517381839B1 (enExample)
SG (1) SG11201704897QA (enExample)
TW (2) TWI698436B (enExample)
WO (1) WO2016109515A1 (enExample)
ZA (1) ZA201704746B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299533B2 (en) 2011-09-02 2025-01-01 Incyte Holdings Corp Heterocycloamines as PI3K inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
EP3200589A4 (en) 2014-09-10 2018-07-25 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
SG11201706917WA (en) 2015-02-27 2017-09-28 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
CA3012560A1 (en) * 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
WO2017201683A1 (en) * 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109563094B (zh) 2016-06-10 2022-03-18 法国施维雅药厂 新的(杂)芳基取代的哌啶基衍生物、它们的制备方法和含有它们的药物组合物
FR3061177B1 (fr) * 2016-12-28 2019-09-27 Les Laboratoires Servier Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2018009812A1 (en) 2016-07-08 2018-01-11 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
CN108239082B (zh) * 2016-12-26 2021-01-05 成都先导药物开发股份有限公司 一种抑制rock的化合物及其应用
WO2018175188A1 (en) * 2017-03-21 2018-09-27 Temple University-Of The Commonwealth System Of Higher Education Novel modulators of the sigma-2 receptor and their method of use
EP3600289A4 (en) 2017-03-21 2020-08-05 Temple University - Of The Commonwealth System of Higher Education 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS
EP3682881A4 (en) 2017-09-14 2021-08-11 Daiichi Sankyo Company, Limited CONNECTION WITH CYCLICAL STRUCTURE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
AU2018377976A1 (en) 2017-11-29 2020-06-04 Les Laboratoires Servier New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
PT4053128T (pt) 2017-12-15 2024-10-15 Biohaven Therapeutics Ltd Derivados de 5-(2-(2,5-difluorofenil)pirrolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina e compostos relacionados como inibidores de trk cinase para tratamento de cancro
CA3085460A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
AU2019231689A1 (en) 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
CN111918865B (zh) 2018-03-30 2023-10-27 住友化学株式会社 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物
US11528907B2 (en) 2018-04-25 2022-12-20 Bayer Aktiengesellschaft Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
CN112996518A (zh) 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
KR20210102285A (ko) * 2018-12-06 2021-08-19 알막 디스커버리 리미티드 약학적 화합물 및 유비퀴틴 특이적 단백질분해효소 19 (usp19)의 억제제로서의 사용
KR102712818B1 (ko) 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
KR20210100127A (ko) * 2018-12-06 2021-08-13 알막 디스커버리 리미티드 치료용 usp19 억제제
CN109666005A (zh) * 2018-12-14 2019-04-23 上海毕得医药科技有限公司 一种2-溴恶唑-5-甲酸乙酯的合成方法
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
CA3125353A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
US20220125760A1 (en) 2019-02-14 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
CN109912598B (zh) * 2019-03-27 2022-09-13 四川大学华西医院 防治炎症反应的核苷类衍生物及其应用
WO2020207352A1 (zh) * 2019-04-11 2020-10-15 四川科伦博泰生物医药股份有限公司 三嗪酮并咪唑类化合物及其医药用途
EP4524137A3 (en) 2019-05-06 2025-04-30 Icahn School of Medicine at Mount Sinai Heterobifunctional compounds as degraders of hpk1
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
BR112022020114A2 (pt) * 2020-04-15 2022-11-29 Pyramid Biosciences Inc Métodos para preparar inibidores do receptor tirosina quinase
KR20220162155A (ko) * 2020-04-27 2022-12-07 주식회사 오토텍바이오 Ubr 박스 도메인 리간드로의 화합물
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
TW202227405A (zh) * 2020-08-24 2022-07-16 以色列商安道麥馬克西姆有限公司 用於製備經取代的吡唑之方法
WO2022159650A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2
MX2023010467A (es) 2021-03-10 2023-11-22 Jnana Therapeutics Inc Inhibidores de molecula peque?a de la funcion de slc6a19 de mamifero.
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
EP4373487A4 (en) * 2021-07-19 2025-10-29 Baylor College Medicine CORONAVIRUS MAJOR PROTEASE INHIBITORS AND THEIR METHODS OF USE
WO2023003973A1 (en) * 2021-07-20 2023-01-26 Dana-Farber Cancer Institute, Inc. Inhibitors targeting ubiquitin specific protease 7 (usp7)
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
GB202200753D0 (en) * 2022-01-21 2022-03-09 Almac Discovery Ltd Pharmaceutical compounds
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
EP4467535A1 (en) 2023-05-25 2024-11-27 Basf Se Lactam pesticidal compounds
WO2024240859A1 (en) 2023-05-25 2024-11-28 Basf Se Lactam pesticidal compounds
TW202515554A (zh) * 2023-08-11 2025-04-16 美商杰那醫療公司 Slc6a19功能之含雙環雜芳基之哌啶抑制劑
CN118496138B (zh) * 2024-07-10 2024-12-03 西北农林科技大学深圳研究院 一种l-氮杂环丁烷-2-羧酸的合成方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
IN151496B (enExample) 1980-02-26 1983-05-07 Chamanlal Jagannath Shishoo
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US20120165319A1 (en) 1995-12-20 2012-06-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
IL132474A (en) 1997-05-08 2003-05-29 Agrevo Uk Ltd 3,4-dihydrothienopyrimidine-4-(thi) ones for combating plant fungi and a novel such compound
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US20030153598A1 (en) 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
ES2275670T3 (es) 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. Metodos novedosos utilizando inhibidores de colinesterasa.
ES2222389T3 (es) 2000-06-07 2005-02-01 Almirall Prodesfarma, S.A. Derivados de 6-fenilpirrolopirimidindiona.
US6506771B2 (en) 2000-06-23 2003-01-14 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl heterobicyclic factor Xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US20020169175A1 (en) 2001-02-05 2002-11-14 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of heterocyclic compounds
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
AU2002340232A1 (en) 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
US7501417B2 (en) 2002-03-13 2009-03-10 Janssen Pharmaceutica, N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
WO2003092606A2 (en) 2002-05-01 2003-11-13 Eisai Co., Ltd. Cholinesterase inhibitors to prevent injuries caused by chemicals
US20070053976A1 (en) 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003301662A1 (en) * 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
ATE368666T1 (de) 2003-03-18 2007-08-15 Jordanian Pharmaceutical Mfg Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
TW200519116A (en) 2003-08-26 2005-06-16 Teijin Pharma Ltd Pyrrolopyrimidine derivatives
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
WO2005087226A1 (en) 2004-03-05 2005-09-22 Eisai Co., Ltd. Cadasil treatment with cholinesterase inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
DK1737831T3 (da) 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
EP1779867A4 (en) 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
US20060172992A1 (en) 2004-08-13 2006-08-03 Eisai Co., Ltd. Therapeutic agent for overactive bladder resulting from cerebral infarction
US20060135507A1 (en) 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
CA2584412C (en) * 2004-09-14 2017-05-09 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
AU2005320134B2 (en) 2004-12-24 2011-04-28 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
WO2006118320A1 (ja) 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited チエノピリミドン化合物
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
RU2008129873A (ru) 2005-12-23 2010-01-27 Новартис АГ (CH) Конденсированные гетероциклические соединения, полезные в качестве ингибиторов дпп-iv
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2008112715A2 (en) 2007-03-12 2008-09-18 Vm Discovery Inc. Novel agents of calcium ion channel modulators
CN101730703B (zh) 2007-03-16 2012-12-26 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
US20100184706A1 (en) * 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
RU2341527C1 (ru) 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
RU2345996C1 (ru) 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
CA2706018C (en) * 2007-11-30 2015-11-24 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2719362A1 (en) 2008-04-04 2009-10-08 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110082158A1 (en) 2008-10-01 2011-04-07 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US8927718B2 (en) 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
EP2488520B1 (en) 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
US8575114B2 (en) 2010-03-23 2013-11-05 Albany Molecular Research, Inc. SGLT-2 inhibitors, methods of making them, and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2663311A2 (en) * 2011-01-10 2013-11-20 GlaxoSmithKline LLC Pyrimidinone derivatives as fatty acid synthase inhibitors
GB201107768D0 (en) 2011-05-10 2011-06-22 Univ Manchester Riboswitches
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
US9802904B2 (en) 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
CN103833646A (zh) 2014-02-28 2014-06-04 广东工业大学 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂

Also Published As

Publication number Publication date
MX2020002963A (es) 2020-07-22
US20160185785A1 (en) 2016-06-30
AU2015374170A1 (en) 2017-07-27
EA038204B1 (ru) 2021-07-22
MX2017008604A (es) 2017-11-15
AU2015374170B2 (en) 2020-10-22
TWI770525B (zh) 2022-07-11
MA40706A1 (fr) 2018-02-28
SA517381839B1 (ar) 2022-05-30
CN107406451B (zh) 2019-12-17
CN107406451A (zh) 2017-11-28
MX373788B (es) 2020-03-23
CA2972797A1 (en) 2016-07-07
KR20170106981A (ko) 2017-09-22
TWI698436B (zh) 2020-07-11
EP3623372A1 (en) 2020-03-18
HK1246284A1 (zh) 2018-09-07
US9902728B2 (en) 2018-02-27
EA201791507A1 (ru) 2018-01-31
ES2768996T3 (es) 2020-06-24
TW201639847A (zh) 2016-11-16
EP3240791B1 (en) 2019-11-06
TW202115067A (zh) 2021-04-16
JP6649388B2 (ja) 2020-02-19
US20210332052A1 (en) 2021-10-28
PH12017501224A1 (en) 2018-01-15
ZA201704746B (en) 2025-10-29
JP2018500376A (ja) 2018-01-11
CO2017006997A2 (es) 2017-10-20
SG11201704897QA (en) 2017-07-28
US10934299B2 (en) 2021-03-02
EP3240791A1 (en) 2017-11-08
US20190367525A1 (en) 2019-12-05
ECSP17049010A (es) 2017-11-30
AR103297A1 (es) 2017-05-03
BR112017013692A2 (pt) 2018-01-09
CA2972797C (en) 2023-12-05
US12018030B2 (en) 2024-06-25
AU2021200346A1 (en) 2021-03-18
WO2016109515A1 (en) 2016-07-07
US10377760B2 (en) 2019-08-13
IL252773A0 (en) 2017-08-31
US20180339988A1 (en) 2018-11-29
KR102581827B1 (ko) 2023-09-25

Similar Documents

Publication Publication Date Title
CL2017001687A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina.
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
MX2021014955A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
HK1246285A1 (zh) 作为泛素特异性蛋白酶7(usp7)抑制剂用於治疗癌症的吡咯并三嗪酮和咪唑并三嗪酮衍生物
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
HK1248221A1 (zh) 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
MY199711A (en) Bicyclic heterocycles as fgfr inhibitors
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
HK1248222A1 (zh) 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
EA201992022A1 (ru) Терапевтическая рнк
EA201890489A1 (ru) Car макрофагов (moto-car) в иммунотерапии
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1